Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
Status:
Completed
Trial end date:
2013-09-30
Target enrollment:
Participant gender:
Summary
Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein
associated phospholipase A2 (Lp-PLA2) currently under clinical development by GlaxoSmithKline
as a potential anti-atherosclerosis agent for reduction of major adverse cardiovascular (CV)
events in patient populations with chronic coronary heart disease and after an acute coronary
syndrome.
This study will determine the effect of repeated administration of diltiazem on the
pharmacokinetics of a repeated administration of darapladib. A drug interaction study with a
moderate CYP3A4 inhibitor is warranted to provide guidance to prescribing physicians.